Progress in the Treatment of Hematological Diseases with Rituximab

Fu, Xiangjun and Lin, Li’e and Yao, Hongxia and Huang, Li and Meng, Can and Wang, Shuwen and Liu, Dan and Guo, Li and Duan, Mengling (2021) Progress in the Treatment of Hematological Diseases with Rituximab. Open Journal of Blood Diseases, 11 (01). pp. 6-14. ISSN 2164-3180

[thumbnail of ojbd_2021022616033239.pdf] Text
ojbd_2021022616033239.pdf - Published Version

Download (306kB)

Abstract

Rituximab is a mouse and human chimeric CD20 (anti-B cell) specific monoclonal antibody that has been approved by the U.S. Food and Drug Administration for the treatment of lymphoma. The expression of CD20 antigen is expressed in the whole ontogeny of B cells, starting from the premature B cells in bone marrow to the differentiation of plasma cells in secondary lymphoid tissues. The wide distribution of CD20 molecules allows rituximab to eliminate a large number of B cells. Rituximab is the core drug for the treatment of hematological diseases, often combined with drugs as a first-line treatment. Long-term hormone therapy often results in serious adverse reactions, and new therapies, which can avoid widespread immunotoxicity, have great potential for treating diseases of the blood system.

Item Type: Article
Subjects: Euro Archives > Medical Science
Depositing User: Managing Editor
Date Deposited: 13 Sep 2023 04:42
Last Modified: 13 Sep 2023 04:42
URI: http://publish7promo.com/id/eprint/3028

Actions (login required)

View Item
View Item